1-3 of 3
Jingtao Wu
Close
Sort by
Journal Articles

KP104, a Bifunctional C5 Antibody/Factor H Fusion Protein, Effectively Controls Both Intravascular and Extravascular Hemolysis: Interim Results from a Phase 2 Study in Complement Inhibitor-Naïve PNH Patients

Fengkui Zhang, Li Zhang, Chen Yang, Chunrong Wang, Changhe Yue, Hui Yan, Jay Ma, Helen Fu, Chaomei He, Ping Tsui, Jingtao Wu, Richard Lee, Wenru Song, Bing Han
Journal: Blood
Blood (2023) 142 (Supplement 1): 572.
https://doi.org/10.1182/blood-2023-186453
Published: 2023
Journal Articles

Trial in Progress: An Open-Label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria

Fengkui Zhang, Bing Han, Guangsheng He, Hu Zhou, Chunrong Wang, Changhe Yue, Jay Ma, Martin Rabe, Helen Fu, Chaomei He, Ping Tsui, Jingtao Wu, Frederick Beddingfield, Wenru Song, Richard Lee
Journal: Blood
Blood (2022) 140 (Supplement 1): 11459–11460.
https://doi.org/10.1182/blood-2022-159172
Published: 2022
Journal Articles

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms ( CYP2C19 , ABCB1 , PON1 ), Non-Compliance, Diet, Smoking, Co-Medications (including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function

Andrew L. Frelinger, III, PhD, Deepak L. Bhatt, MD, MPH, Ronald D. Lee, PhD, Darcy J. Mulford, PhD, Jingtao Wu, PhD, Sai Nudurupati, PhD, Anu Nigam, MS, Michael Lampa, BS, Julie K. Brooks, MS, Marc R. Barnard, MS, Alan D. Michelson, MD
Journal: Blood
Blood (2012) 120 (21): 4356.
https://doi.org/10.1182/blood.V120.21.4356.4356
Published: 2012